Analysis of drug therapy for coronavirus disease 2019 in renal transplant recipients
Objective To investigate the therapeutic effects of nirmatrelvir/ritonavir and azvudine in renal transplant re-cipients infected with coronavirus disease 2019(COVID-19).Methods Clinical data of patients with COVID-19 after renal transplantation from December 20,2022 to January 26,2023 at Xijing Hospital of Air Force Military Medical University were collected and the treatment protocols and outcomes of different patients were summarized.Results A total of 14 patients were included in the study.Among 5 patients(cases 1 to 5)treated with azvudine monotherapy,four patients showed an increase in absolute lymphocyte count and a decrease in NLR compared to before treatment.For four patients(cases 6 to 9)treated with nirmatrelvir/ritonavir monotherapy,absolute lymphocyte count increased and NLR decreased compared to before treat-ment.For five patients(cases 10 to 14)who were initially treated with azvudine for 1 week,a decrease in absolute lympho-cyte count and an increase in the infection range on chest CT were observed.Azvudine was discontinued,and after switching to oral Nirmatrelvir/ritonavir treatment,the absolute value of lymphocyte count increased,and chest CT indicated a reduction in the lesion range.All patients were followed up 6 months after discharge.One patient developed graft kidney failure,one pa-tient died due to cerebral infarction and multiple organ failure,eight patients had elevated creatinine values compared to base-line levels,and four patients had creatinine values at or below baseline levels.Conclusion For renal transplant recipients with secondary COVID-19,azvudine or nirmatrelvir/ritonavir is indicated.If azvudine treatment is not effective,it may be discon-tinued and switched to oral nirmatrelvir/ritonavir therapy.
NETL
NSTL
万方数据
